Lipoproteins and PCSK9 bound to receptors. Computer illustration of low-density lipoprotein (LDL), or 'bad' cholesterol, molecules (round) and molecules of the enzyme proprotein convertase subtilisin/kexin type 9 (PCSK9, blue) bound to LDL receptor (LDLR) proteins (Y-shaped) in a cell surface (bottom). When there are high levels of LDL cholesterol in the blood it builds up on the sides of blood vessels hardening them, a condition named atherosclerosis. This narrows the blood vessels and may block them. LDL receptors recognise and bind to LDL molecules to remove them from the bloodstream. When PCSK9 binds to an LDLR, the receptor is destroyed along with the LDL particle. But if PCSK9 does not bind, the receptor can return to the surface of the cell and remove more cholesterol. PCSK9 inhibitor drugs reduce the amount of cholesterol in the blood by improving the liver's ability to recycle LDLRs.
Model release not required. Property release not required.